Biogen

Company Overview

Biogen Inc. is a global biopharmaceutical company focused on developing and delivering drugs for complex and hard-to-treat diseases, such as rare and neurogenerative diseases. Founded in 1978, Biogen focuses on conditions like multiple sclerosis (MS), Alzheimer’s disease, and spinal muscular atrophy (SMA). The company is known for its leading MS treatments and continues working on innovative neuroscience therapies. In addition to branded drugs, the company also manufactures and markets biosimilars.

Its primary monoclonal antibody (mAb) includes Tysabri (natalizumab) for treating multiple sclerosis and Crohn’s. Biosimilars include Flixabi (adalimumab), Tofidence (tocilizumab-bavi) and Imraldi (infliximab). Other products include Avonex, Plegridy, Tecfidera, Vumerity, Ocrevus, Qalsody, Fampyra, Fumaderm, Skyclarys, Benepali, and Byooviz.

LEQEMBI (lecanemab-irmb- developed in collaboration with Eisai Co., Ltd).

Financial Highlights (FY 2024)

Company's Business Segments

• Multiple Sclerosis : The segment develops, manufactures, and markets various products designed to treat patients with M.S.
• Rare Disease : This segment includes SPINRAZA for SMA and SKYCLARYS for F.A., which was obtained as part of its acquisition of Reata in.
• Biosimilars : September 2023 and QALSODY for ALS, which became commercially available in the U.S. during Q2, 2023.
• Others Revenue : Revenue from anti-CD20 therapeutic programs, Alzheimer's collaboration revenue, Contract manufacturing, royalty and other revenue